Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLTNYSE:CANONASDAQ:RNXTNASDAQ:SHLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.38+1.6%$0.39$0.30▼$10.62$52.95M1.863.41 million shs2.69 million shsCANOCano Health$3.81$1.74▼$190.00$12.39M0.05423,785 shs159,142 shsRNXTRenovoRx$1.35-2.2%$1.20$0.75▼$1.69$50.47M1.3297,311 shs141,776 shsSHLTSHL Telemedicine$2.05$2.05$1.85▼$5.10$33.61M0.1111,182 shsN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics+1.60%+8.42%-0.99%-26.40%-91.48%CANOCano Health0.00%0.00%0.00%0.00%0.00%RNXTRenovoRx-2.17%-2.17%+8.87%+35.00%+19.47%SHLTSHL Telemedicine0.00%0.00%0.00%-2.15%-61.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics4.3078 of 5 stars3.33.00.04.72.21.71.3CANOCano HealthN/AN/AN/AN/AN/AN/AN/AN/ARNXTRenovoRx2.9842 of 5 stars3.55.00.00.02.71.70.0SHLTSHL TelemedicineN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.50Moderate Buy$6.101,505.26% UpsideCANOCano Health 0.00N/AN/AN/ARNXTRenovoRx 3.00Buy$7.25437.04% UpsideSHLTSHL Telemedicine 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CANO, SHLT, RNXT, and APLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $11.505/19/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.005/14/2025APLTApplied TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.504/28/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $11.004/4/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/27/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$460K116.96N/AN/A$0.49 per share0.78CANOCano Health$2.74B0.00N/A0.03$100.28 per share0.00RNXTRenovoRx$40K1,234.24N/AN/A$0.19 per share7.11SHLTSHL Telemedicine$55.94M0.60$0.04 per share54.03$5.21 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.43N/AN/AN/AN/A-184.67%-84.02%8/6/2025 (Estimated)CANOCano Health-$207.27M-$215.87N/AN/AN/A-18.62%-133.59%-19.18%N/ARNXTRenovoRx-$8.81M-$0.40N/AN/AN/AN/A-119.58%-88.01%8/12/2025 (Estimated)SHLTSHL Telemedicine-$7.06MN/A0.00∞N/AN/AN/AN/AN/ALatest CANO, SHLT, RNXT, and APLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RNXTRenovoRx-$0.08-$0.08N/A-$0.08$0.23 million$0.20 million4/14/2025Q4 2024APLTApplied Therapeutics-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million3/31/2025Q4 2024RNXTRenovoRx-$0.12-$0.13-$0.01-$0.12$0.17 million$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACANOCano HealthN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/ASHLTSHL TelemedicineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A3.003.00CANOCano Health3.950.400.40RNXTRenovoRxN/A9.079.07SHLTSHL Telemedicine0.192.171.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%CANOCano Health35.99%RNXTRenovoRx3.10%SHLTSHL Telemedicine20.11%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%CANOCano Health13.93%RNXTRenovoRx9.13%SHLTSHL TelemedicineN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30141.58 million139.31 millionOptionableCANOCano Health4,3655.41 million4.65 millionOptionableRNXTRenovoRx636.57 million33.23 millionNot OptionableSHLTSHL Telemedicine58316.39 millionN/ANot OptionableCANO, SHLT, RNXT, and APLT HeadlinesRecent News About These CompaniesSHL Telemedicine ADR Stock Price HistoryJune 20, 2025 | investing.comSHL Telemedicine Clarifies Voting Process for May 2025 AGMMay 20, 2025 | tipranks.comSHL Telemedicine to Delist ADRs from Nasdaq to Cut CostsMarch 11, 2025 | tipranks.comSHLT SHL Telemedicine Ltd.March 6, 2025 | seekingalpha.comSHL Telemedicine Ltd (SHLTN)January 23, 2025 | investing.comSHL Telemedicine (NASDAQ:SHLT) Stock Quotes, Forecast and News SummaryDecember 18, 2024 | benzinga.comDocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular CareDecember 18, 2024 | businesswire.comSHL Telemedicine (NASDAQ:SHLT) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comSHL Telemedicine to Appoint David Arnon as CEO of SHL TelemedicineJuly 29, 2024 | 01net.it0SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli ActivityJune 20, 2024 | businesswire.comSHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood TestMay 21, 2024 | businesswire.comSHL Telemedicine Ltd ADR - NewMay 17, 2024 | morningstar.comMSHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft LaunchMay 16, 2024 | finance.yahoo.comSHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft LaunchMay 16, 2024 | businesswire.comSHL Telemedicine Ltd.: SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical MilestonesApril 17, 2024 | finanznachrichten.deSHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical MilestonesApril 17, 2024 | finance.yahoo.comSHL Telemedicine Ltd. (SHLT)April 16, 2024 | finance.yahoo.comTelehealth clinical trial cuts hospital cardiac readmissions by 76%April 11, 2024 | msn.comImperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient CareApril 11, 2024 | finance.yahoo.comImperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient CareApril 11, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCANO, SHLT, RNXT, and APLT Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.38 +0.01 (+1.60%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$0.38 0.00 (-1.05%) As of 06/26/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Cano Health NYSE:CANOCano Health, Inc. provides primary care medical services to its members in the United States and Puerto Rico. It owns and operates medical centers enabled by CanoPanorama, a proprietary population health management technology-powered platform that provides the healthcare providers at its medical centers with a 360-degree view of their members with actionable insights to improve care decisions and member engagement. The company also operates pharmacies, as well as provides dental services in its medical centers. Cano Health, Inc. was founded in 2009 and is headquartered in Miami, Florida.RenovoRx NASDAQ:RNXT$1.35 -0.03 (-2.17%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.35 0.00 (0.00%) As of 06/26/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.SHL Telemedicine NASDAQ:SHLT$2.05 0.00 (0.00%) As of 04/16/2025SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
